NCT00191607View on ClinicalTrials.gov

A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.

PHASE3CompletedINTERVENTIONAL

Enrollment

162

Participants

Timeline

Start Date

July 31, 2002

Study Completion Date

November 30, 2005

Conditions

Genital Neoplasms, FemaleFallopian Tube NeoplasmsOvarian NeoplasmsPelvic NeoplasmsPeritoneal Neoplasms

Interventions

DRUG

Gemcitabine

DRUG

liposomal doxorubicin

Trial Locations (1)

63110

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT00191607 - A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. | Biotech Hunter | Biotech Hunter